Ischemix named "Duffy" DuFresne as its new chief executive. Reinier Beeuwkes, the previous chief executive, will continue to advise the company as president and chairman.
Hollis-Eden Pharmaceuticals has fired Richard Hollis, the company's founding CEO.
Exact Sciences Corp. said that President and Chief Executive Jeffrey Luber and Chief Financial Officer Charles Carelli Jr. have both resigned.
Pfizer has named Elizabeth Barrett as regional president, U.S. for its oncology business unit, where she will lead sales, field operations, and marketing.
Valeant Pharmaceuticals has appointed Dr. Bhaskar Chaudhuri to the position of president, Valeant Pharmaceuticals International.
Protox Therapeutics announced that John Parkinson has been appointed chief financial officer.
Alvine Pharmaceuticals announced the appointment of Dr. Daniel Adelman as senior vice pPresident, development and chief medical officer.
etrials Worldwide said that E. James (Jim) Emerson, Ph.D. has been named as the company's vice president of technology and development.
EnzymeRx says that Elizabeth John is joining the company as vice president, manufacturing. She most recently had been head of research and development at Centegen. The company also welcomed John Zhang as vice president, preclinical research and development.
Traversa Therapeutics has named William Kaelin, Jr., M.D. and Yitzhak Tor, Ph.D. to the company's scientific advisory board.
Accera announced that Thomas Werner, Ph.D. has been elected to its board of directors
Allos Therapeutics has named David Stout, former president, pharmaceuticals at GlaxoSmithKline, to the company's board of directors.
Brainstorm Cell Therapeutics has elected Malcolm Taub to the company's board of directors.
Auxilium Pharmaceuticals has appointed William McKee as its new independent director and as a member of the board's audit and compliance committee.
N30 Pharma announced that Joseph Loscalzo, M.D., PhD., has joined the board.
VasoGenix Pharmaceuticals announced today that Judith Hemberger, Ph.D., has been elected to its board of directors.
Oxygen Biotherapeutics has appointed Melville Engle to its board of directors.